Roche Holding AG
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT01750957
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT01750697
- Locations
- πΊπΈ
Hackensack University Medical Center, Hackensack, New Jersey, United States
π¨π¦The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
πΊπΈThe Cleveland Clinic Foundation; Rheumatic and Immunologic Diseases, Cleveland, Ohio, United States
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT01748773
- Locations
- πΉπ·
Marmara Uni Faculty of Medicine; Medical Oncology, Istanbul, Turkey
πΉπ·Baskent University Medical Faculty; Internal Medicine, Ankara, Turkey
πΉπ·Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 61
- Registration Number
- NCT01749150
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
- Conditions
- Malignant Melanoma
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2016-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 420
- Registration Number
- NCT01744860
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Tocilizumab
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01741688
- Locations
- π΅πͺ
Clinica San Borja; Servicio De Reumatologia, Lima, Peru
π΅πͺClinica El Golf, San Isidro, Peru
π΅πͺABK Reuma SRL- Medicentro BioCiencias, Lima, Peru
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT01739218
- Locations
- π«π·
Chu D'Amiens, Amiens, France
π«π·HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
π«π·Institut Bergonie; Oncologie, Bordeaux, France
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 215
- Registration Number
- NCT01739764
- Locations
- πΊπΈ
Siouxland Regional Cancer Center d/b/a June E. Nylen Cancer Center, Sioux City, Iowa, United States
πΊπΈEvelyn H. Lauder Center, New York, New York, United States
πΊπΈUniversity of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT01734993
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01734018